ѧÊõÌÃÊ×Ò³ | ÎÄÏ×ÇóÖúÂÛÎÄ·¶ÎÄ | ÂÛÎÄÌâÄ¿ | ²Î¿¼ÎÄÏ× | ¿ªÌⱨ¸æ | ÂÛÎĸñʽ | ÕªÒªÌá¸Ù | ÂÛÎÄÖÂл | ÂÛÎIJéÖØ | ÂÛÎÄ´ð±ç | ÂÛÎÄ·¢±í | ÆÚ¿¯ÔÓÖ¾ | ÂÛÎÄд×÷ | ÂÛÎÄPPT
ѧÊõÌÃרҵÂÛÎÄѧϰƽ̨Äúµ±Ç°µÄλÖãºÑ§ÊõÌà > ҽѧÂÛÎÄ > »ù´¡Ò½Ñ§ÂÛÎÄ > Ò©ÀíѧÂÛÎÄ

Ñ̲ÝÖÐÄá¹Å¶¡¶ÔËû¿ËĪ˾ÓÕµ¼ÉöÔàËðÉ˵ļÓÖØÑо¿

À´Ô´£ºÖйúÀÏÄêѧÔÓÖ¾ ×÷ÕߣºÕžºÔÂ,½ðº£·å,Àî²Ó,
·¢²¼ÓÚ£º2021-06-17 ¹²6774×Ö

¡¡¡¡Õª    Òª£º¡¡Ä¿µÄ ̽ÌÖÑ̲ÝÖÐÖ÷Òª¶¾ÐԳɷÖÄá¹Å¶¡(NIC)ÊÇ·ñ¼ÓÖØËû¿ËĪ˾(TAC)ÓÕµ¼µÄÉöÔàËðÉË¡£·½·¨ ½«32Ö»ÐÛÐÔSD´óÊó·ÖΪÕý³£¶ÔÕÕ×é(VH)×é¡¢TAC×é¡¢NIC×é¡¢NIC+TAC×飬ÿ×é8Ö»¡£¸÷×é·Ö±ð¸øÓèéÏé­ÓÍ¡¢TAC¡¢NIC¡¢NIC+TAC¸ÉÔ¤4 w¡£¼ì²â¸÷×éÉú»¯¡¢Éö¹¦ÄÜ¡¢Äòµ°°×ÅÅйÁ¿¡¢ÉöС¹Ü¼äÖÊÏËά»¯(TIF)³Ì¶È£¬ÃâÒß×黯ºÍWesternÓ¡¼£·¨·Ö±ð¼ì²âÖÂÏËÒò×Ó¡¢Ï¸°ûµòÍöÏà¹Ø»ùÒòµÄ±í´ï¡£½á¹û ÓëTAC×é±È½Ï£¬NIC+TAC×éѪ¼¡ôû(Scr)¡¢ÑªÄòËصª(BUN)¡¢Äòµ°°×ÅÅйÁ¿ÏÔ×ÅÉý¸ß£¬ÉöС¹Ü¼äÖÊÏËά»¯(TIF)³Ì¶È¡¢ÉöСÇòϵĤÇøÃæ»ýÏÔ×ÅÀ©´ó£¬×ª»¯Éú³¤Òò×Ó(TGF)-β1±í´ïÏÔ×ÅÔö¼Ó£»ÑªÇå¼°ÄòÅÅй8-ôÇÍÑÑõÄñÜÕ(8-OHdG)ÏÔ×ÅÔö¼Ó£¬³¬Ñõ»¯ÎïÆ绯ø(SOD)1¡¢SOD2±í´ïÏÔ׎µµÍ£¬NADPHÑõ»¯Ã¸(NOX)-2¡¢NOX-4±í´ïÏÔ×ÅÔö¼Ó£»BÁÜ°Íϸ°ûÁö(Bcl)-2/Bcl-2Ïà¹ØXµ°°×(Bax)±ÈÖµÏÔ׎µµÍ£¬»î»¯µÄÌ춬°±ËáÌØÒìÐÔ°ëë×°±Ëáµ°°×ø(Cleaved caspase)-3ÏÔ×ÅÔö¼Ó£¬Ô­Î»È±¿ÚÄ©¶Ë±ê¼Ç(TUNEL)·¨ÏÔʾTUNELÑôÐÔϸ°ûÊýÏÔ×ÅÔö¼Ó(¾ùP<0.05)¡£½áÂÛ NIC¼ÓÖØÁËTACÓÕµ¼µÄÉöËðÉË£¬Æä»úÖÆ¿ÉÄÜÓëNIC¼ÓÖØÑõ»¯Ó¦¼¤ºÍϸ°ûµòÍöÓйأ¬°µÊ¾½äÑÌ¿ÉÄܶԷþÓÃTACµÄÒÆÖ²ÎüÑÌÕßÓÐÒæ¡£

¡¡¡¡¹Ø¼ü´Ê :     Äá¹Å¶¡;Ëû¿ËĪ˾;Ñõ»¯Ó¦¼¤;ϸ°ûµòÍö;

¡¡¡¡Abstract£º¡¡Objective To investigate whether nicotine(NIC), a major toxic component of cigarette smoking, exacerbates tacrolimus(TAC)-induced renal injury. Methods Sprague-Dawley rats were treated daily with NIC, TAC, or both drugs for 4 weeks. The influence of NIC on TAC-caused renal injury was examined via renal function, histopathology, expression of fibrotic mediators, oxidative stress, and apoptosis related gene.Results Both NIC and TAC significantly impaired renal function and histopathology, while combined NIC and TAC treatment aggravated these parameters beyond the effects of either alone. Oxidative stress was increased, the expression of fibrotic mediators and apoptosis related gene from either NIC or TAC were also exacerbated by the two combined.Conclusions NIC could exacerbate chronic TAC nephrotoxicity, which suggests that smoking cessation might be beneficial to transplant smokers taking TAC.

¡¡¡¡Keyword£º¡¡Nicotine; Tacrolimus; Oxidative stress; Cell apoptosis;
 

Ñ̲ÝÖÐÄá¹Å¶¡¶ÔËû¿ËĪ˾ÓÕµ¼ÉöÔàËðÉ˵ļÓÖØÑо¿
 

¡¡¡¡Ëû¿ËĪ˾(TAC)×÷ΪһÖַdz£ÓÐЧµÄÃâÒßÒÖÖƼÁ£¬Òѱ»¹ã·ºÓ¦ÓÃÓÚÆ÷¹ÙÒÆÖ²¡¢×ÔÉíÃâÒßÐÔ¼²²¡¡¢½áµÞ×éÖ¯²¡¡¢ÄÑÖÎÐÔÉö²¡×ÛºÏÕ÷µÄÖÎÁÆ£¬¾¡¹Ü·¢ÏÖÁ˲»ÉÙеÄÃâÒßÒÖÖƼÁ£¬TACÈÔÊÇʵÌåÆ÷¹ÙÒÆÖ²ÃâÒßÒÖÖÆ·½°¸µÄ»ùʯ¡£È»¶ø£¬³¤ÆÚʹÓÃTAC»áÔö¼Ó²»Á¼·´Ó¦µÄ·çÏÕ(ÈçÉö¶¾ÐÔ¡¢Éñ¾­¶¾ÐÔ¡¢¸ÐȾ¡¢¶ñÐÔÖ×Áö¡¢ÌÇÄò²¡ºÍ賦µÀ²»ÊÊ)¡£ÖÚËùÖÜÖª£¬ÎüÑÌÊǵ¼Ö¸÷ÖÖ°©Ö¢¡¢ÐÄѪ¹Üʼþ(Ðļ¡¹£ËÀºÍÄÔ×äÖÐ)ºÍ×èÈûÐԷβ¡µÄΣÏÕÒòËØ¡£ÎüÑÌÊÇÒ»ÏîÖØ´óµÄ¹«¹²ÎÀÉúÌôÕ½£¬¸øÉç»á´øÀ´¾­¼Ã¸ºµ££¬½µµÍÉú»îÖÊÁ¿¡£ÔÚÉöÔà·½Ã棬ÎüÑÌ»á¼ÓÖØÌÇÄò²¡¡¢¸ßѪѹ¡¢¶àÄÒÉöºÍÉöÒÆÖ²Êõºó»¼ÕßµÄÉö¹¦Äܲ»È«³Ì¶È[1]¡£ÎüÑÌ»¹¿ÉÄܵ¼ÖÂÉöËðÉË£¬¼´Ê¹ÊDz»´æÔÚÂýÐÔÉöÔಡ(CKD)µÄ½¡¿µÈËȺ[2]¡£Äá¹Å¶¡(NIC) ×÷ΪÑ̲ÝÖеÄÌìÈ»³É·Ö£¬ÓгÉñ«ÐÔ¼°¶¾ÐÔ×÷Óã¬ÊǶÔÈËÌå²úÉúÓк¦Ó°ÏìµÄ×ï¿ý»öÊ×Ö®Ò»¡£ÎüÑÌÊÇÉöÔ༲²¡µÄÒ»¸öÖØÒªÇÒ¿É¿ØÖƵÄΣÏÕÒòËØ£¬±¾Ñо¿Í¨¹ýNIC´¦ÀíTACÓÕµ¼µÄÉöËðÉË´óÊóÄ£ÐÍ£¬Ì½ÌÖNIC¼ÓËÙÆäÉö¶¾ÐԵĿÉÄÜ»úÖÆ¡£

¡¡¡¡1¡¢ ²ÄÁÏÓë·½·¨

¡¡¡¡1.1¡¢ ʵÑ鶯Îï¼°·Ö×é

¡¡¡¡½«32Ö»ÌåÖØΪ200¡«220 gµÄÇå½à¼¶ÐÛÐÔSD´óÊó(Ñӱߴóѧ¶¯ÎïʵÑéÖÐÐĹºÂò) ,·Ö±ðÖÃÓں㶨ζȡ¢Êª¶È¡¢¹âÕÕ¿ØÖƵĻ·¾³ÖУ¬²¢ÔÊÐí×ÔÓÉÉãÈëµÍÑÎÒûʳ(0.05%ÑÎËÇÁÏ£¬µÍÑÎÒûʳÔöÇ¿TACÉö¶¾ÐÔ) ºÍ×ÔÀ´Ë®¡£ÊÊÓ¦»·¾³¡¢µÍÑÎÒûʳºÍ×ÔÓÉÒûË®ºó£¬ÌåÖØÆ¥ÅäµÄ´óÊóËæ»ú·ÖΪ4×飬ÿ×é8Ö»¡£¢ÙÕý³£¶ÔÕÕ×é(VH×é):ƤÏÂ×¢ÉäéÏé­ÓÍ1 ml/(kg·d)¡£¢ÚNIC×飺ƤÏÂ×¢ÉäéÏé­ÓÍ1 ml/(kg·d)+¸¹Ç»×¢ÉäNIC 1.5 mg/(kg·d)¡£¢ÛTAC×飺ƤÏÂ×¢ÉäTAC 1.5 mg/(kg·d)¡£¢ÜTAC+NIC×飺ƤÏÂ×¢ÉäTAC 1.5 mg/(kg·d)+ ¸¹Ç»×¢ÉäNIC 1.5 mg/(kg·d)¡£¸÷×é¾ùÿÈÕ9¡Ã00¸øÒ©£¬¹²´¦Àí4 wºó´¦ËÀ´óÊó£¬ÊÕ¼¯ÑªÒº¡¢ÄòÒº¡¢Éö×éÖ¯±ê±¾ÒÔ±¸½øÒ»²½¼ì²â¡£±¾ÊµÑéͨ¹ýÑӱߴóѧ¸½ÊôÒ½ÔºÂ×ÀíίԱ»áÅú×¼(YBU-2017-045)¡£

¡¡¡¡1.2 ¡¢Éú»¯¼ì²â

¡¡¡¡È«×Ô¶¯Éú»¯·ÖÎöÒDzⶨѪ°×ϸ°û¼ÆÊý(ADVIA 120 ,ÈÕ±¾°Ý¶ú¹«Ë¾);±ê׼ø±ÈÉ«·¨²â¶¨Ñª¼¡ôû(Scr) ¼°ÑªÄòËصª(BUN)(Stanbio Lahoratory, Boeme, TX, USA);May-Grun-wald Giemsa Ⱦɫ·¨¼ÆÊýÁÜ°Íϸ°ûÊý£¬Ê¹ÓøßЧҺÏà-´®ÁªÖÊÆ×·¨²â¶¨TACѪҩŨ¶È(TAC con);Äòµ°°×ÅÅйÁ¿²â¶¨²ÉÓÃøѧ±ÈÉ«·¨(Modular DPP system, Roche)¡£Ê¹ÓÃøÁªÃâÒßÎü¸½ÊÔÑé(ELISA)²â¶¨ÑªÇåºÍÄòÅÅйÖÐ8-ôÇ»ùÍÑÑõÄñÜÕ(8-OHdG);²ÉÓÃøÁªÃâÒßÎü¸½ÊÔÑé(ELISA)ÊÔ¼ÁºÐ(Calbiotech, San Diego, CA) ²â¶¨´óÊóѪÇåºÍÄòÖеĿÉÌæÄþ¡£

¡¡¡¡1.3 ¡¢ÉöÔಡÀí

¡¡¡¡ÉöÔà×éÖ¯ÓɹýµâËá-Àµ°±Ëá-¶à¾Û¼×È©Òº(PLP) ¹Ì¶¨£¬¹ýµâËáÑ©·ò(PAS)Ⱦɫ£¬Ê¯À¯°üÂñºó4 μmÇÐƬ£¬Masson ÈýɫȾɫ£¬²ÉÓòÊɫͼÏñ×Ô¶¯·ÖÎöÒÇ(Olympus, ÈÕ±¾)¸ß±¶¾µÊÓÒ°Ï·ÖÎöÉöС¹Ü¼äÖÊÏËά»¯(TIF)³Ì¶È£¬ ÿ¸ö±ê±¾ÖÁÉÙ¹Û²ì 20 ¸ö·ÇÖصþÉöС¹Ü¼äÖÊȡƽ¾ùÖµ¡£

¡¡¡¡1.4¡¢ WesternÓ¡¼£·¨

¡¡¡¡Éö×éÖ¯±ê±¾ÖÃÓÚ¹ÜÖУ¬¼ÓÈëµ°°×ÖÊ»º³åÒº(10 mmol/LÈýôǼ׻ù°±»ù¼×ÍéÑÎËáÑΣ¬pH7.6;150 mmol/mlÂÈ»¯ÄÆ£¬1%ÍÑÑõµ¨ËáÄÆ£¬1%¾ÛÒÒ¶þ´¼ÐÁ»ù±½»ùÃÑ£¬0.1%Ê®¶þÍé»ùÁòËáÄÆ£¬1%ÒÖøëÄ£¬2 mmol/LËÄÑõà×ण¬1 ng/mlÁÁÒÖøëÄ£¬1 mmol/L±½¼×»ù»Çõ£·ú»¯Îï),ÊÒÎÂÔȽ¬¡£È»ºóÔÚ4¡æÏ£¬13 000 r/minÀëÐÄ£¬È¡ÉÏÇåÒº£¬ÓÃBio-Radµ°°×²â¶¨ÊÔ¼ÁºÐ²â¶¨×ܵ°°×Ũ¶È¡£È¡Í¬µÈÁ¿µÄÔȽ¬ÔÚÊ®¶þÍé»ùÁòËáÄÆ-¾Û±ûÏ©õ£°·Äý½ºÉϽøÐеçÓ¾¡£ÔÚ90 VµçѹÏÂתµ½ÏõËáÏËάËØĤ2 h¡£½þÈë5%ÍÑÖ¬ÄÌ·ÛÖзâ±Õ2 h, ÔÚ4¡æÏ·ֱðµÎ¼ÓÒ»¿¹NADPHÑõ»¯Ã¸(NOX)-2(1¡Ã500)¡¢NOX-4(1¡Ã500)¡¢BÁÜ°Íϸ°ûÁö(Bcl)-2(1¡Ã500)¡¢×ª»¯Éú³¤Òò×Ó(TGF)-β1(1¡Ã500)¡¢Bcl-2Ïà¹ØXµ°°×(Bax)(1¡Ã500)¡¢³¬Ñõ»¯ÎïÆ绯ø(SOD)1(1¡Ã500)¡¢ SOD2(1¡Ã500)¡¢Ì춬°±ËáÌØÒìÐÔ°ëë×°±Ëáµ°°×ø(Cleaved caspase)-3(1¡Ã500)],Ò»¿¹Óë5%ÍÑÖ¬ÄÌ·Û»ìºÏ£¬»ºÂýÒ¡°Ú£¬4¡æϹýÒ¹¡£TBST·´¸´Ï´Ä¤3´Î£¬¼Ó¶þ¿¹4 h; TBST·´¸´³åÏ´¾ÛÆ«·úÒÒÏ©(PVDF)Ĥ3´Î£¬Ò¡´²³åÏ´10 min¡£Ê¹Óõ绯ѧÔöÇ¿(ECL)ÊÔ¼ÁÔöÇ¿·¢¹â£¬ÔÚ°µÊÒϽºÆ¬Æع⣬ºó²É¼¯Í¼Ïñ¡£Ê¹ÓÃͼÏñ·ÖÎöÒÇ(Quantity One) ½øÐÐWesternÓ¡¼£Í¼Ïñ·ÖÎö¡£

¡¡¡¡1.5¡¢ ԭλȱ¿ÚÄ©¶Ë±ê¼Ç(TUNEL)

¡¡¡¡¸ù¾Ý ApopTag in Situ Apoptosis Detection(Millipore)ÊÔ¼ÁºÐ²Ù×÷²½Öè²â¶¨Ï¸°ûµòÍö£¬200¸ß±¶ÏÂÊý×Ö»¯ÏÔ΢¾µ·ÖÎöÒǼÆÊýTUNEL ÑôÐÔϸ°û¡£

¡¡¡¡1.6 ¡¢Í³¼Æѧ·½·¨

¡¡¡¡²ÉÓÃSPSS19.0 Èí¼þ½øÐе¥ÒòËØ·½²î·ÖÎö(Oneway ANOVA)ºÍ Bonferroni post hoc УÕý·ÖÎö¡£

¡¡¡¡2 ¡¢½á ¹û

¡¡¡¡2.1¡¢ NIC¶Ô»ù±¾Êý¾Ý¼°Éö¹¦ÄܵÄÓ°Ïì

¡¡¡¡ÓëVH×é±È½Ï£¬TAC×éÄòÁ¿Ã÷ÏÔÔö¼Ó£¬¶øNIC+TAC×éÄòÁ¿½ÏTAC×é½øÒ»²½Ôö¼Ó(P<0.05);TAC×é¡¢NIC×éÄòµ°°×¡¢BUN¡¢Scrˮƽ¾ùÃ÷ÏÔÉý¸ß(P<0.05),¶øNIC+TAC×éµÄÄòµ°°×¡¢BUN¡¢Scrˮƽ½ÏTAC×é½øÒ»²½Éý¸ß(P<0.05),ÌáʾNIC¼ÓÖØTACÓÕµ¼µÄÉö¹¦Äܲ»È«¡£¸øÒ©4 wºó£¬ÑªÖÐTACŨ¶ÈÔö¼Ó£¬¶øNICÔò²»Ó°ÏìѪTACŨ¶È£¬¼û±í1¡£

¡¡¡¡±í1 ¸÷×é»ù±¾²ÎÊý¼°ÊµÑéÊÒ¼ì²â½á¹û(x??±s,n=8)
±í1 ¸÷×é»ù±¾²ÎÊý¼°ÊµÑéÊÒ¼ì²â½á¹û(x??¡Às,n=8)

¡¡¡¡2.2¡¢ NIC¶ÔTACÓÕµ¼µÄÉöÏËά»¯¼°ÉöСÇòÓ²»¯µÄÓ°Ïì

¡¡¡¡TAC×éÓëNIC×éÉö×éÖ¯TIF³Ì¶ÈÃ÷ÏÔÔö¼Ó£¬NIC+TAC×éÉö×éÖ¯TIF³Ì¶È½ÏTAC×éÃ÷ÏÔÔö¼Ó£¬¼ûͼ1¡£WesternÓ¡¼£·¨½á¹ûÏÔʾ£¬ÓëVH×é[(107.50±15.26)%]Ïà±È£¬TAC×é[(192.90±17.14)%]ÓëNIC×é[(189.50±12.58)%]Éö×éÖ¯ÖÐTGF-β1±í´ïÁ¿Ã÷ÏÔÔö¼Ó£¬NIC+TAC×é[(253.20±22.56)%]Éö×éÖ¯ÖÐTGF-β1±í´ïÁ¿½ÏTAC×éÃ÷ÏÔÔö¼Ó(P<0.05),ÌáʾNICÔöÇ¿ÁËTACÓÕµ¼µÄ´ÙÏËά»¯TGF-β1¹ý±í´ï¡£¼ûͼ2¡£

¡¡¡¡Í¼1 ¸÷×éÉö×éÖ¯TIF³Ì¶È±È½Ï(Masson, ×200)
ͼ1 ¸÷×éÉö×éÖ¯TIF³Ì¶È±È½Ï(Masson, ¡Á200)

¡¡¡¡Í¼2 WesternÓ¡¼£·¨¼ì²â¸÷×éÉö×éÖ¯TGF-β1µÄ±í´ï
ͼ2 WesternÓ¡¼£·¨¼ì²â¸÷×éÉö×éÖ¯TGF-¦Â1µÄ±í´ï

¡¡¡¡ÓëVH×é[(1.34±0.58)%]Ïà±È£¬TAC×éÓëNIC×éÉö×éÖ¯PASȾɫϵĤÃæ»ý[(16.23±1.99¡¢14.48±1.56)%]Ã÷ÏÔÔö¼Ó£¬ ¶øNIC+TAC×éµÄÉö×éÖ¯ÖÐPASȾɫϵĤÃæ»ý[(22.24±2.17)%]½ÏTAC×éÃ÷ÏÔÔö¼Ó(¾ùP<0.05)¡£¼ûͼ3¡£

¡¡¡¡Í¼3 ¸÷×éÉö×éÖ¯²¡ÀíÐÎ̬ѧ±ä»¯(PAS,×1 000)
ͼ3 ¸÷×éÉö×éÖ¯²¡ÀíÐÎ̬ѧ±ä»¯(PAS,¡Á1 000)

¡¡¡¡2.3¡¢ NIC¶ÔTACÓÕµ¼µÄÑõ»¯Ó¦¼¤µÄÓ°Ïì

¡¡¡¡ÓëVH×é±È½Ï£¬TAC×éÓëNIC×éѪÇå¼°ÄòÅÅй8-OhdGº¬Á¿¾ùÃ÷ÏÔÔö¶à(¾ùP<0.05),NIC+TAC×éѪÇå¼°ÄòÅÅй8-OHdGº¬Á¿½ÏTAC×éÃ÷ÏÔÔö¶à(P<0.05),¼û±í2¡£

¡¡¡¡±í2 ¸÷×éѪ¼°ÄòÖÐ8-OHdGˮƽµÄ±È½Ï(x??±s,n=8,ng/ml)
±í2 ¸÷×éѪ¼°ÄòÖÐ8-OHdGˮƽµÄ±È½Ï(x??¡Às,n=8,ng/ml)

¡¡¡¡ÓëVH×éÏà±È£¬TAC×éÓëNIC×éÉö×éÖ¯ÖÐSOD1¡¢SOD2±í´ï½µµÍ£¬NIC+TAC×éÉö×éÖ¯ÖÐSOD1¡¢SOD2µÄ±í´ï½ÏTAC×éÃ÷ÏÔ½µµÍ¡£¼û±í3¡¢Í¼4¡£TAC×éÓëNIC×éÉö×éÖ¯ÖÐNOX-2¡¢NOX-4µÄ±í´ïÉý¸ß£¬NIC+TAC×éÉö×éÖ¯ÖÐNOX-2¡¢NOX-4µÄ±í´ï½ÏTAC×éÃ÷ÏÔÉý¸ß¡£¼û±í3¡¢Í¼5¡£ÉÏÊö·ÖÎöÏÔʾ£¬NICÉϵ÷ÁËTACÓÕµ¼µÄNOX2ºÍNOX4µÄ±í´ï£¬¶øÒÖÖÆÁËSOD1ºÍSOD2µÄ±í´ï£¬ËµÃ÷ÔÚ±¾Ä£ÐÍÖÐNICºÍTAC¶ÔÑõ»¯Ó¦¼¤ÓÐЭͬ×÷Óá£

¡¡¡¡±í3 ¸÷×éÉö×éÖ¯SOD1¡¢SOD2¡¢NOX-2¡¢NOX-4¡¢Bcl-2/Bax¡¢Cleaved caspase-3µÄWesternÓ¡¼£±í´ïÁ¿(x??±s,n=8,%)
±í3 ¸÷×éÉö×éÖ¯SOD1¡¢SOD2¡¢NOX-2¡¢NOX-4¡¢Bcl-2/Bax¡¢Cleaved caspase-3µÄWesternÓ¡¼£±í´ïÁ¿(x??¡Às,n=8,%)

¡¡¡¡Í¼4 ¸÷×éÉö×éÖ¯ÖÐSOD1¡¢SOD2±í´ï
ͼ4 ¸÷×éÉö×éÖ¯ÖÐSOD1¡¢SOD2±í´ï

¡¡¡¡Í¼5 ¸÷×éÉö×éÖ¯NOX-2¡¢NOX-4±í´ï
ͼ5 ¸÷×éÉö×éÖ¯NOX-2¡¢NOX-4±í´ï

¡¡¡¡2.4¡¢ NIC¶ÔTACÓÕµ¼µÄϸ°ûµòÍöµÄÓ°Ïì

¡¡¡¡´ó¶àÊýTUNELÑôÐÔϸ°û»òµòÍöСÌ嶨λÓÚÉöС¹ÜÉÏƤϸ°ûºÍ¼äÖÊѪ¹ÜÄÚƤϸ°û£¬ÓÈÆäÊÇήËõµÄÉöС¹ÜºÍµäÐ͵ÄTIFÇøÓò¡£ÓëVH×é(0.8±0.1)mm2±È½Ï£¬TAC×éÓëNIC×éÉö×éÖ¯ÖÐTUNELÑôÐÔϸ°ûÊýÁ¿[(9.6±0.8)¡¢(3.8±0.2)]mm2Ã÷ÏÔÔö¼Ó£¬NIC + TAC×éÉö×éÖ¯ÖÐTUNELÑôÐÔϸ°ûÊýÁ¿(13.9±0.4)mm2½ÏTAC×éÃ÷ÏÔÔö¼Ó¡£¼ûͼ6¡£WesternÓ¡¼£½á¹ûʾ£¬ÓëVH×é±È½Ï£¬NIC×éÓëTAC×éÉö×éÖ¯ÖÐBcl-2/Bax±ÈÖµ½µµÍ£¬NIC+TAC×éÉö×éÖ¯ÖÐBcl-2/Bax±ÈÖµ½ÏTAC×éÃ÷ÏÔ½µµÍ¡£TAC×éÓëNIC×éÉö×éÖ¯ÖлµÄCaspase-3Éý¸ß£¬NIC + TAC×éÉö×éÖ¯ÖлµÄCaspase-3½ÏTAC×éÃ÷ÏÔÉý¸ß¡£¼û±í3¡¢Í¼7¡£

¡¡¡¡Í¼6 ¸÷×éÉöС¹ÜTUNELÑôÐÔϸ°ûÊý(×200)
ͼ6 ¸÷×éÉöС¹ÜTUNELÑôÐÔϸ°ûÊý(¡Á200)

¡¡¡¡Í¼7 ¸÷×éÉö×éÖ¯ÖÐBcl-2¡¢BaxºÍCleaved caspase-3µÄ±í´ï
ͼ7 ¸÷×éÉö×éÖ¯ÖÐBcl-2¡¢BaxºÍCleaved caspase-3µÄ±í´ï

¡¡¡¡3 ¡¢ÌÖ ÂÛ

¡¡¡¡ÎÞÂÛÊǽ¡¿µÈËȺ£¬»¹ÊÇÓлù´¡¼²²¡(Èç¸ßѪѹ¡¢ÌÇÄò²¡)µÄ»¼Õߣ¬ÎüÑÌÊÇÒ»¸ö¿É¿ØÖƵÄÒýÆðCKD½øÕ¹µÄΣÏÕÒòËØ[3]¡£Ñо¿±íÃ÷£¬NIC»áÔö¼ÓÉöÔàµÄÑõ»¯Ó¦¼¤£¬´Ó¶øËðº¦ÉöС¹ÜºÍÄÚƤϸ°ûµÄ»îÁ¦ºÍ¹¦ÄÜ£¬¸Ä±äÉöÔàѪÁ÷¶¯Á¦Ñ§£¬Ëðº¦ÕûÌåÉöÔ๦ÄÜ[4]¡£´ËÍ⣬NICÔöǿϵĤÔöÉú¡¢Ó°Ïìϸ°ûÔöÖ³ÓëµòÍö¡¢´Ù½øϸ°ûÍâ»ùÖʶѻýºÍ´Ù½øÉöÏËά»¯Í¾¾¶À´Ëðº¦ÉöÔ๦ÄÜ[2,5,6]¡£ÁÙ´²ÊÔÑé±íÃ÷£¬ÎüÑÌ¿ÉÔö¼ÓÄò°×µ°°×ÅÅйÁ¿£¬¶ÔÉö¹¦ÄܲúÉú²»ÀûÓ°Ï죬¶ø½äÑÌ¿ÉÄܸÄÉƵ°°×ÄòºÍÉöСÇòÂ˹ýÂÊ£¬Í¬Ê±Ò²¿ÉÄܸÄÉÆCKDºÍ2ÐÍÌÇÄò²¡»¼Õߵĵ°°×Äò£¬²¢¼õ»ºÖÕÄ©ÆÚÉöË¥½ß(ESRD)µÄ½øÕ¹[7,8,9]¡£´ËÍ⣬ÎÞÂÛÊÇÒÆÖ²ÎïÊÜÌ廹Êǹ©Ì壬ÎüÑ̶¼»áµ¼ÖÂÒÆÖ²ÅųⷴӦºÍÂýÐÔÒÆÖ²ÎïÉö²¡(CAN),×îÖÕµ¼ÖÂÉöÒÆÖ²ÖеÄÒÆÖ²Îﶪʧ[10,11]¡£ÌáʾÎüÑÌ¿ÉÄÜ»á¼ÓËÙ½ÓÊÜ»ùÓÚTACµÄÃâÒßÒÖÖƼÁµÄÒÆÖ²Éö¹¦ÄܵÄɥʧ¡£

¡¡¡¡×÷ΪÓÐЧÇÒ¾ßÓÐÁ¼ºÃÄÍÊÜÐÔµÄÁÙ´²ÃâÒßÒÖÖƼÁ£¬TACµÄ³¤ÆÚʹÓÿɵ¼ÖÂÉöСÇòϵĤϸ°ûºÍ»ùÖÊÔö¶à¡¢Ð¡¶¯Âö͸Ã÷ÖÊËá³Á»ý¡¢ÉöС¹ÜήËõ¡¢ÉöСÇòÓ²»¯ºÍÉöÔà¼äÖÊÏËά»¯£¬×îÖÕ²úÉú²»¿ÉÄæµÄÉöÔàËðÉË¡£±¾ÎÄ˵Ã÷NICµ¼ÖÂÉöÔàËðÉË£¬ÓëÏÈÇ°Ñо¿Ò»ÖÂ[12]¡£È»¶øÉö¶¾ÐÔÄ£ÐÍ´óÊóÓÃNIC´¦ÀíºóÉö¹¦ÄÜËðÉËÖ¸±ê½øÒ»²½Éý¸ß£¬±íÃ÷NIC¼ÓÖØTACÓÕµ¼µÄÉöËðÉË¡£

¡¡¡¡ÂýÐÔTACÉö¶¾ÐÔµÄÖ÷Òª¸Ä±äÔÚÓÚÉöС¹Ü¼äÖÊÇø£¬ÈçÉöС¹Ü»ùµ×ĤÔöºñ¡¢ÉöС¹ÜήËõºÍÉöС¹ÜÏËά»¯¡£±¾Ñо¿·¢ÏÖ£¬NIC¼ÓÖØÁËTACÓÕµ¼µÄ²¿·ÖϵĤÃæ»ýÔö¼ÓºÍTIF³Ì¶È¡£ÕâЩ²¡Àí¸Ä±äÒýÆð¸üÃ÷ÏÔµÄÉö¹¦ÄÜË𺦺ÍÄòµ°°×ÅÅйµÄÔö¼Ó¡£ÌáʾÎüÑÌ¿ÉÄܼӿì½ÓÊÜÃâÒßÒÖÖƼÁÖÎÁÆ»¼ÕßµÄÉö¹¦ÄÜËðÉË¡£½äÑÌ¿ÉÄܳÉΪÑÓ»º»òÖÎÁÆÉöÔàÏËά»¯µÄÖØÒªÊֶΡ£

¡¡¡¡ÂýÐÔTACÉöËðÉËÊǶàÖÖÒòËع²Í¬µ¼ÖµĽá¹û£¬TACÉöËðÉËÓëÑõ»¯Ó¦¼¤Ö®¼ä´æÔÚÃÜÇйØϵ¡£Ñõ»¯Ó¦¼¤ÊÇÒòΪÑõ»¯»¹Ô­ÏµÍ³Ôâµ½ÆÆ»µ£¬´Ó¶ø²úÉú´óÁ¿µÄ»îÐÔÑõ¡£×î½ü´óÁ¿Ñо¿±íÃ÷£¬ÂýÐÔNIC±©Â¶ÓëÉöÔàËðÉ˵ÄÑõ»¯Ó¦¼¤Ö®¼ä´æÔÚÃÜÇйØϵ[13,14]¡£Ñõ»¯Ó¦¼¤ÔÚTIF¼°ÉöСÇòϵĤӲ»¯¡¢×ãϸ°ûÒì³£ºÍ¶¥Ò¶ÉÏƤϸ°ûËðÉ˵ÄÉöСÇòÓ²»¯ÖÐÆð×ÅÖÁ¹ØÖØÒªµÄ×÷ÓÃ[15]¡£8-OHdG×÷ΪÌåÄÚDNAÑõ»¯ËðÉË·ÖÃÚ×îÖÕ²úÎïµÄ±êÖ¾Îһ°ãÐî»ýÔÚÉö¼äÖʺÍÉöС¹ÜÖУ¬ÇÒÓë»úÌåÑõ»¯ËðÉ˳̶ȳÊÕýÏà¹Ø¡£SODÊÇÌåÄÚÖØÒªµÄ¿¹Ñõ»¯¼Á£¬ÔÚά³Ö»úÌåÑõ»¯Ó뿹Ñõ»¯µÄƽºâÖÐÆð×ÅÖÁ¹ØÖØÒªµÄ×÷Óá£ËüÄÜ×è¶Ï×ÔÓÉ»ùµ¼ÖµÄÖ¬ÖʹýÑõ»¯Éú³É£¬±£»¤Æä²»ÊÜ×ÔÓÉ»ùµÄËðº¦[16]¡£½üÄêÀ´¶àÖÖ²»Í¬µÄÉöÔಡÀíÄ£ÐÍÖз¢ÏÖNADPHÑõ»¯Ã¸¼Ò×å(NOXs) ´Ù½øÉöÔàÑõ»¯Ó¦¼¤µÄ·¢Éú¡£NOX-2ºÍNOX-4ÊÇÍÌÊÉϸ°ûÖÐNADPHÑõ»¯Ã¸µÄ´ß»¯ÑÇ»ù¡£NOX-2µÄ¼¤»î³ÆΪÑõ»¯±¬·¢£¬´Ù½ø»îÐÔÑõµÄÉú³É£¬µ¼ÖÂÉöÔàËðÉË¡£Ö£Üç×ÓµÈ[17]Ñо¿·¢ÏÖ£¬ÒÖÖÆNADPHÑõ»¯Ã¸ÏµÍ³¿É¼õÇá´óÊóÉö¼äÖÊÏËά»¯¡£±¾Ñо¿ËµÃ÷NICÔö¼ÓÁËÑõ»¯µ°°×µÄ±í´ï£¬Í¬Ê±ÒÖÖÆÁË¿¹Ñõ»¯µ°°×µÄ±í´ï£¬´Ó¶ø¼ÓÖØÁËTACÓÕµ¼µÄÑõ»¯Ó¦¼¤ºÍÉöÔàÏËά»¯¡£

¡¡¡¡Ï¸°ûµòÍöÊdzÌÐòÐÔϸ°ûËÀÍöµÄÒ»ÖÖ¶ÀÌØÐÎʽ¡£¸Ã¹ý³ÌÔÚ·¢ÓýºÍά³ÖÄÚ»·¾³µÄÎȶ¨ÖÐÆð×ÅÖÁ¹ØÖØÒªµÄ×÷Óá£TACÓÕµ¼µÄÉöËðÉËÓë½ü¶ËÉöС¹Üϸ°ûµòÍöÓйء£NICͨ¹ýÑõ»¯Ó¦¼¤»ò¼¤»îTGF-β1ÓÕµ¼×ãϸ°ûºÍÉö½ü¶ËС¹Üϸ°ûµòÍö[18,19]¡£Bcl-2ÊÇÒÖÖƵòÍö»ùÒò¡£BaxÊÇBcl-2µ°°×¼Ò×åµÄÒ»Ô±£¬µ±BaxÓëÏßÁ£ÌåÍâĤ½áºÏʱ»áÆô¶¯Ï¸°ûµòÍö;¾¶£¬´Ó¶ø¸Ä±äÆäͨ͸ÐÔ²¢ÊͷŵòÍöµ°°×¡£µòÍöBaxºÍ¿¹µòÍöBcl-2µ°°×Ö®¼äµÄƽºâʧºâ£¬ÔÚÆô¶¯µòÍö;¾¶µÄ¹ý³ÌÖз¢»ÓÖÁ¹ØÖØÒªµÄ×÷ÓÃ[20]¡£Caspase-3ÊǵòÍöϸ°ûËÀÍöµÄÖ´ÐÐÕߣ¬Æ伤»î±»ÈÏΪÊÇϸ°ûËÀÍöµÄÒ»ÖÖ³Ðŵ[21]¡£Ï¸°ûºÍ×éÖ¯ÖÐCaspase-3»îÐÔ¼ì²âÊǶàÖÖµòÍöÐźÅÓÕµ¼µÄϸ°ûµòÍöµÄÖØÒª·½·¨¡£ÉÏÊöÑо¿±íÃ÷£¬TACºÍNIC¾ùÓÕµ¼Ï¸°ûµòÍö£¬¶øNICÄܹ»¼ÓÖØTACÓÕµ¼µÄϸ°ûµòÍö£¬´Ó¶ø½øÒ»²½µ¼ÖÂÉöÔàËðÉË¡£

¡¡¡¡×ÛÉÏ£¬NICÔÚTACÂýÐÔÉö¶¾ÐÔ´óÊóÄ£ÐÍÖмÓÖØÁËTACÓÕµ¼µÄÉöËðÉË¡£Ñõ»¯Ó¦¼¤µÄ¼ÓÖغͳÌÐòÐÔϸ°ûËÀÍö¿ÉÄÜÊÇNICÓк¦×÷ÓõÄÒ»¸öDZÔÚ»úÖÆ¡£

¡¡¡¡²Î¿¼ÎÄÏ×

¡¡¡¡[1] Luo K,Lim SW,Jin J,et al. Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties[J]. BMC Nephrol,2019;20(1):221.
¡¡¡¡[2] Jain G,Jaimes EA.Nicotine signaling and progression of chronic kidney disease in smokers[J]. Biochem Pharmacol,2013;86:1215-23.
¡¡¡¡[3] Formanek P, Salisbury-Afshar E, Afshar M.Helping patients with ESRD and earlier stages of CKD to quit smoking[J]. Am J Kidney Dis ,2018;72(2)-255-66.
¡¡¡¡[4] Arany I,Taylor M,Fulop T,et al.Adverse effects of chronic nicotine exposure on the kidney:potential human health implications of experimental findings[J].Int J Clin Pharmacol Ther,2018;56(11):501-6.
¡¡¡¡[5] Crotty AL, Drummond CA,Hepokoski M,et al. Chronic inhalation of e-cigarette vapor containing nicotine disrupts airway barrier function and induces systemic inflammation andmultiorgan fibrosis in mice[J] .Am J Physiol Regul Integr Comp Physiol,2018;314():834-47.
¡¡¡¡[6] Arany l,Reed DK. Grifoni SC,et al.A novel U-STAT3-dependent mechanism mediates the deleterious effects of chronic nicotine exposure on renal injury[J.Am J Physiol Renal
¡¡¡¡Physiol,2012;302(6):722-9.
¡¡¡¡[7] Popa SG,Mota M,Mihaltan FD,et al.Associations of smoking with cardiometabolic profile and renal function in a Romanian population-based sample from the PREDATORR cro
¡¡¡¡ss-sectional study[J].Eur J Gen Pract,2017;23(1):164-70.
¡¡¡¡[8] Noborisaka Y,Ishiz aki M.Nakata M,et al.Cigarette smoking.proteinuria,and renal function in middle-aged Japanese men from an occupational population[J] Environ Health PrevMed,2012;17(2):147-56.
¡¡¡¡[9] Pinto-Sietsma SJ,Mulder J,Janssen WM,et al. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons[J] Ann Intern Med,2000;133:585-91.
¡¡¡¡[10] Heldt J,Torrey R,Han D,et al.Donor smoking negatively affects donor and recipient renal function fllowing living donor nephrectomy[J] Adv Urol,2011;2011:929263.
¡¡¡¡[11] Sung RS,Althoen M,Howell TA.et al. Excess risk of renal allograft loss associated with cigarette smoking[J] Transplantation,2001;71:1752-7.
¡¡¡¡[12] Ramalingam A,Santhanathas T,Shaukat AS,et al. Resveratrol supplementation protects against nicotine-induced kidney injury[J].Int J Environ Res Public Health,2019;16(22):445.
¡¡¡¡[13]Chang YW,Singh KP Nicotine-induced oxidative stress contributes to EMT and stemness during neoplastic transformation through epigenetic modifications in human kidney e
¡¡¡¡pithelial cells[J].Toxicol Appl Pharmacol,2019;374:65-76.
¡¡¡¡[14] Zahran WE ,Emam MA.Renoprotective effect of spirulina platensis extract against nicotine-induced oxidative stress-mediated inflammation in rats[J] Phytomedicine,2018;49:106-10.
¡¡¡¡[15] Su H,Wan C,Song A,et al. Oxidative stress and renal fibrosis.mechanisms and therapies[J].Adv Exp Med Biol,209;1165:585-604.
¡¡¡¡[16]ÁõÆôÏé,л¼Ò¶÷,ÕÅÁ¢¶¬, µÈ¶¡Ïã·Ó¶Ô´óÊóÉöȱѪÔÙ¹à×¢ÐÔËðÉ˱£»¤×÷ÓõÄÑо¿[J.ÁÙ´²ºÍʵÑéҽѧÔÓÖ¾, 2017;16(13): 1261-4.
¡¡¡¡[17]Ö£Üç×Ó,ÇüÀÚ,ÌƼÎÞ±,µÈÒÖÖÆNADPHÑõ»¯Ã¸ÏµÍ³¿É¼õÇáµ¥²àÊäÄò¹Ü¹£×è´óÊóÉö¼äÖÊÏËά»¯[J].ÖлªÉöÔಡÔÓÖ¾, 2014;30(6):437-42.

×÷Õßµ¥Î»£ºÑӱߴóѧ¸½ÊôÒ½ÔºÉö²¡¿Æ
Ô­Îijö´¦£ºÕžºÔÂ,½ðº£·å,Àî²Ó,½ð»ª.Äá¹Å¶¡¼ÓÖØÂýÐÔËû¿ËĪ˾Éö¶¾ÐԵĻúÖÆ[J].ÖйúÀÏÄêѧÔÓÖ¾,2021,41(10):2121-2126.
Ïà¹Ø±êÇ©£º
  • ±¨¾¯Æ½Ì¨
  • ÍøÂç¼à²ì
  • ±¸°¸ÐÅÏ¢
  • ¾Ù±¨ÖÐÐÄ
  • ´«²¥ÎÄÃ÷
  • ³ÏÐÅÍøÕ¾